Market Challenges: High Cost and Rise in Adverse Drug Reaction

The high cost of drugs used to treat treatment resistant depression is anticipated to hinder market growth in the forecast period. For example, in March 2020, Johnson & Johnson, a multinational pharmaceutical and biotechnology company, announced the pricing of its nasal spray depression treatment, Spravato, at US$ 590 for a 56 mg dose and US$ 885 for an 84 mg dose, which may pose financial challenges for patients seeking this medication. The high cost of drugs used to treat treatment resistant depression is significantly restraining the growth of Treatment Resistant Depression Market. Treatment resistant depression refers to a condition where individuals do not respond to at least two antidepressant treatments of adequate dose and duration in the current depressive episode. While the exact prevalence is unknown, it is estimated that nearly 30–50% of individuals with major depressive disorder have treatment resistant depression.

Market Opportunities: Promising Opportunities in Treatment resistant Depression

The current drug pipeline is promising and includes new molecular entities targeting neurotransmitter pathways beyond serotonin and norepinephrine. Advances in digital and remote healthcare technologies allow for more precise diagnosis and combination with non-drug therapies. Growing mental health awareness has increased screening and diagnosis rates, highlighting the need for more effective solutions. An improved understanding of depression.

Treatment Resistant Depression Market Report Snapshots